Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM)

NCT07720843 is registered in ClinicalTrials.gov with Montefiore Medical Center as lead sponsor.

NCT NCT07720843
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07720843 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM)
Lead sponsor
Montefiore Medical Center
Phase
Phase 1
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
March 31, 2032
Enrollment
50 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

refractory multiple myeloma, relapse multiple myeloma